Anzeige
Meldung des Tages: Verdoppelt – und noch nicht am Ziel? Dieser Rohstoff-Explorer profitiert vom Antimon-Boom

Immatics News

Aktie
WKN:  A2P72S ISIN:  NL0015285941 US-Symbol:  IMTX Branche:  Biotechnologie Land:  Deutschland
9,98 $
+0,00 $
0,00%
8,5896 € 09.03.26
Depot/Watchlist
Marktkapitalisierung *
1,06 Mrd. €
Streubesitz
0,12%
KGV
-
Index-Zuordnung
-

Immatics News

05.03.26 - GlobeNewswire
Immatics Announces Full Year 2025 Financial Results and Business Update
Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; anzu-...
11.12.25 - GlobeNewswire
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress
IMA203CD8 is a second-​generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalation Manageable tolerability across all dose levels ...
05.12.25 - GlobeNewswire
Immatics Announces $125 Million Underwritten Offering
Houston, Texas and Tuebingen, Germany,  December 05, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-​stage biopharmaceutical company and the ...
17.11.25 - GlobeNewswire
Immatics Announces Third Quarter 2025 Financial Results and Business Update
Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; ...
12.11.25 - GlobeNewswire
Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps  
Company to host conference call and webcast today, November 12, at 8:30 am EST/2:30 pm CET
27.10.25 - GlobeNewswire
Immatics Appoints Amie Krause as Chief People Officer
Houston , Texas and Tuebingen, Germany, October 27, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-​stage biopharmaceutical company and the global ...
20.10.25 - GlobeNewswire
Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium
One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy in 16 patients with metastatic uveal melanoma in the ongoing Phase 1b trial continues to show ...
01.10.25 - GlobeNewswire
Immatics Appoints Venkat Ramanan as Chief Financial Officer
Houston , Texas and Tuebingen, Germany, October 1, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-​stage biopharmaceutical company and the global ...
13.08.25 - GlobeNewswire
Immatics Announces Second Quarter 2025 Financial Results and Business Update
Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: One-time infusion continues to show favorable tolerability as well as strong anti-​tumor activity and durability in 33 ...
31.05.25 - GlobeNewswire
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising ...
13.05.25 - GlobeNewswire
Immatics Announces First Quarter 2025 Financial Results and Business Update
IMA203 PRAME Cell Therapy: Randomized-​controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing and expected to complete enrollment in 2026 ...
23.04.25 - GlobeNewswire
Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting
Houston, Texas and Tuebingen, Germany, April 23, 2025  – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-​stage biopharmaceutical company active in the ...
27.03.25 - GlobeNewswire
Immatics Announces Full Year 2024 Financial Results and Business Update
Randomized-​controlled Phase 3 trial, SUPRAME, to evaluate ACTengine® IMA203 TCR-T (PRAME) in advanced melanoma patients; first patient randomized and enrollment ...

Newssuche

Videos

newspaper
04.03.26 -6,24%
ROHÖL mit Ziel MINUS 40$?!?
Fundierte Strategien für den Handel der wichtigen News in einem Seminarpaket, plus transparenter ... Mehr »